Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts

BMC Medicine

Liam J Murray¹  Marie M Cantwell¹  Carmel Hughes²  Blánaid M Hicks¹  Úna C Mc Menamin¹  Chris R Cardwell¹ 

[1] Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland;School of Pharmacy, Queen’s University Belfast, Belfast, Northern Ireland

关键词: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers;    Mortality;    Prostate cancer;    Breast cancer;    Colorectal cancer;   

Others  :  854981
DOI  :  10.1186/1741-7015-12-28

 received in 2013-08-21, accepted in 2014-01-14,  发布年份 2014

【 摘 要 】

Background

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are commonly prescribed to the growing number of cancer patients (more than two million in the UK alone) often to treat hypertension. However, increased fatal cancer in ARB users in a randomized trial and increased breast cancer recurrence rates in ACEI users in a recent observational study have raised concerns about their safety in cancer patients. We investigated whether ACEI or ARB use after breast, colorectal or prostate cancer diagnosis was associated with increased risk of cancer-specific mortality.

Methods

Population-based cohorts of 9,814 breast, 4,762 colorectal and 6,339 prostate cancer patients newly diagnosed from 1998 to 2006 were identified in the UK Clinical Practice Research Datalink and confirmed by cancer registry linkage. Cancer-specific and all-cause mortality were identified from Office of National Statistics mortality data in 2011 (allowing up to 13 years of follow-up). A nested case–control analysis was conducted to compare ACEI/ARB use (from general practitioner prescription records) in cancer patients dying from cancer with up to five controls (not dying from cancer). Conditional logistic regression estimated the risk of cancer-specific, and all-cause, death in ACEI/ARB users compared with non-users.

Results

The main analysis included 1,435 breast, 1,511 colorectal and 1,184 prostate cancer-specific deaths (and 7,106 breast, 7,291 colorectal and 5,849 prostate cancer controls). There was no increase in cancer-specific mortality in patients using ARBs after diagnosis of breast (adjusted odds ratio (OR) = 1.06 95% confidence interval (CI) 0.84, 1.35), colorectal (adjusted OR = 0.82 95% CI 0.64, 1.07) or prostate cancer (adjusted OR = 0.79 95% CI 0.61, 1.03). There was also no evidence of increases in cancer-specific mortality with ACEI use for breast (adjusted OR = 1.06 95% CI 0.89, 1.27), colorectal (adjusted OR = 0.78 95% CI 0.66, 0.92) or prostate cancer (adjusted OR = 0.78 95% CI 0.66, 0.92).

Conclusions

Overall, we found no evidence of increased risks of cancer-specific mortality in breast, colorectal or prostate cancer patients who used ACEI or ARBs after diagnosis. These results provide some reassurance that these medications are safe in patients diagnosed with these cancers.

【 授权许可】

   
2014 Cardwell et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Maddams J, Utley M, Moller H: Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer 2012, 107:1195-1202.
• [2]de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH: Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013, 22:561-570.
• [3]Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
• [4]Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
• [5]Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11:627-636.
• [6]Goldstein MR, Mascitelli L, Pezzetta F: Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol 2010, 11:817-818.
• [7]Clere N, Corre I, Faure S, Guihot AL, Vessieres E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D: Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010, 127:2279-2291.
• [8]Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH: Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011, 12:65-82.
• [9]Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L: Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case–control study. Br J Clin Pharmacol 2012, 74:180-188.
• [10]Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A: Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011, 123:1729-1736.
• [11]Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S: Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One 2012, 7:e50893.
• [12]Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L: Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012, 344:e2697.
• [13]Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton DP, Game JP, Christiansen PM, Lash TL, Ahern TP: Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 2013, 31:2265-2272.
• [14]Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M: Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 2013, 4:549-556.
• [15]Heinzerling JH, Anthony T, Livingston EH, Huerta S: Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg 2007, 73:230-238.
• [16]Engineer DR, Burney BO, Hayes TG, Garcia JM: Exposure to ACEI/ARB and beta-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol 2013, 6:539-545.
• [17]Ronquist G, Frithz G, Wang YH, Lindeborg T: Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol 2009, 43:32-36.
• [18]Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW: Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011, 129:549-556.
• [19]Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W: Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011, 29:585-593.
• [20]Holmes MD, Hankinson SE, Feskanich D, Chen WY: Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 2013, 139:507-513.
• [21]Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA: Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 2013, 22:168-175.
• [22]Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010, 69:4-14.
• [23]Clinical Practice Research Datalink: Ethical review for CPRD protocols. [http://www.cprd.com/isac/otherinfo.asp webcite]
• [24]British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary. [http://www.bnf.org/bnf/index.htm webcite]
• [25]World Health Organisation: World Health Organisation Collaborating Centre for Drug Statistics Methodology. [http://www.whocc.no/ webcite]
• [26]National Cancer Institute: Prostate cancer treatment. [http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page2 webcite]
• [27]Khan NF, Perera R, Harper S, Rose PW: Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010, 11:1. BioMed Central Full Text
• [28]Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356:29-38.
• [29]Levesque LE, Hanley JA, Kezouh A, Suissa S: Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.
• [30]Etminan M: Pharmacoepidemiology II: the nested case–control study–a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004, 24:1105-1109.
• [31]Essebag V, Platt RW, Abrahamowicz M, Pilote L: Comparison of nested case–control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005, 5:5. BioMed Central Full Text
• [32]Altman DG, Bland JM: Interaction revisited: the difference between two estimates. BMJ 2003, 326:219.
• [33]Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
• [34]Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011, 29:2645-2652.
• [35]Ager EI, Neo J, Christophi C: The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29:1675-1684.
• [36]George AJ, Thomas WG, Hannan RD: The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010, 10:745-759.
• [37]Deshayes F, Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005, 16:293-299.
• [38]Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X: Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 2013, 328:318-324.
• [39]Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C: Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007, 22:577-584.
• [40]Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, Peng JJ: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J (Engl) 2008, 121:2167-2171.